Navigation Links
Evaluation of targeted therapy in ovarian cancer
Date:10/1/2010

Reston, Va. Research reported in the October issue of The Journal of Nuclear Medicine (JNM) shows that a molecular imaging technique may prove useful in early assessment of treatment response for cisplatin-resistant ovarian cancer.

"One of the most promising aspects of molecular imaging is its potential capacity to measure therapy effects long before changes in the tumor size and shape are detected," said Marijke De Saint-Hubert, medical scientist in the Department of Nuclear Medicine at the University Hospital Gasthuisberg, Leuven, Belgium, and one of the authors on an invited perspective article in JNM that comments on the study. It is important to identify response to therapy as early as possible so that ineffective therapies can be discontinued. Patients who are not responding to a given therapy may be suffering from unnecessary side effects and may also be offered potentially more effective treatments.

The chemotherapy drug cisplatin is often effective against ovarian cancer when first given; however, tumors can become resistant to the drug and start growing again, so the need for second-line therapies is pressing. One potential way to overcome cisplatin resistance is to target the mammalian target of rapamycin (mTOR) pathway. The aim of the study was to evaluate the ability of 18F-FLT, a PET probe for cell proliferation, to predict early response to everolimus (an mTOR inhibitor) in a mouse model of subcutaneously transplanted human cisplatin-resistant ovarian cancer.

The study showed that 18F-FLT PET was able to predict early response to mTOR inhibition in a cisplatin-resistant ovarian cancer in mice. The researchers suggest that this technique should be considered for therapeutic assessment in humans. They also point out the technique's potential to non-invasively and longitudinally monitor the efficacy of combination therapy.

"PET imaging could be used to evaluate the treatment's efficacy very early after treatment initiationat a time when conventional criteria based on tumor size measurements are useless," said Nicolas Aide, M.D., Centre for Molecular Imaging at the Peter MacCallum Cancer Centre, East Melbourne, Australia, one of the authors of the study.


'/>"/>

Contact: Jane Kollmer
jkollmer@snm.org
703-326-1184
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. ARMSRx Evaluation of AWP Neutrality
2. Coronary CTA a cost-effective alternative to cardiac catheterization for the evaluation of CAD
3. High-res US: First-line imaging choice for the evaluation of patients with foot drop?
4. The Institute for Health Metrics and Evaluation selects DatStat as the foundation for ground breaking healthcare project
5. Endoscopic ultrasound evaluation is associated with improved outcomes in pancreatic cancer patients
6. Targeted delivery of losartan reduces liver inflammation and scarring
7. Gene-Targeted Cancer Fix Could Be a Breakthrough
8. Survival in metastatic breast cancer patients is improving: targeted therapies have contributed
9. Targeted agent blocked growth of deadly brain cancer in preclinical studies
10. Kaiser Permanente Southern California to Offer FitOrbit Online Personal Training to Targeted Patients
11. New targeted therapy effective in treating advanced prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... ... according to survey data released today by the American Society for Dermatologic ... indicates the percentage of consumers considering a cosmetic medical procedure has doubled ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... Harbour ... manage token assets on the Ethereum blockchain, has released their technical specifications . ... now, there has been little systematic approach for determining which offerings will garner the ...
(Date:6/27/2017)... ... June 27, 2017 , ... The Congressional Budget Office (CBO) projects ... replace the 2010 Patient Protection and Affordable Care Act (ACA), would result in 22 ... expected under current law. , More than 20 million Americans have gained health insurance ...
(Date:6/27/2017)... ... ... From June 20-22, EarQ and Widex held an exclusive training ... EarQ is headquartered. , Together, the organizations educate hearing care professionals on how ... the latest in hearing technology. At the event, EarQ members got an in-depth ...
(Date:6/27/2017)... ... ... Two residents from the Gardant-managed assisted living and memory care communities in South ... protect Medicaid funding. , The video, which was produced by the American Health Care ... Cathy Schwarz, a couple who is still able to see each other every day ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... , June 7, 2017  Novavax, Inc., (Nasdaq: ... of two Phase 2 trials of its RSV F protein ... child bearing age have been published in the journal ... have been shared in prior scientific conferences). The Company previously ... April 2014. Novavax is developing the RSV F Vaccine with ...
(Date:6/2/2017)... -- NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical technology company focused ... positive biochemical outcomes related to more frequent hemodialysis with ... be presented at the ERA-EDTA Congress being held June ... The research was conducted by the ... Europe (KIHDNEy) Cohort team with ...
(Date:5/29/2017)... Biotechnology Ltd. (NASDAQ: APOP ; TASE: APOP), a ... of stem cells, today provided a corporate update and ... 31 st , 2017. "We are ... of 2017," said Dr. Shai Yarkoni, Chief Executive Officer. ... the first blood cancer patient in the recently initiated ...
Breaking Medicine Technology: